- Home
- PCVX vs CZR Comparison
PCVX vs CZR Comparison
Compare PCVX & CZR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PCVX | CZR |
|---|---|---|
| Founded | 2013 | 1937 |
| Country | United States | United States |
| Employees | N/A | 15500 |
| Industry | Biotechnology: Pharmaceutical Preparations | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.0B | 6.0B |
| IPO Year | 2020 | 2015 |
Fundamental Metrics
Financial Performance| Metric | PCVX | CZR |
|---|---|---|
| Price | $54.07 | $29.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 13 |
| Target Price | ★ $88.25 | $31.92 |
| AVG Volume (30 Days) | 991.2K | ★ 3.3M |
| Earning Date | 05-07-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $1,473,504,000.00 |
| Revenue This Year | N/A | $3.56 |
| Revenue Next Year | N/A | $2.48 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.03 |
| 52 Week Low | $29.10 | $17.86 |
| 52 Week High | $65.00 | $30.88 |
Technical Indicators
Market Signals| Indicator | PCVX | CZR |
|---|---|---|
| Relative Strength Index (RSI) | 51.26 | 48.05 |
| Support Level | $52.04 | $29.46 |
| Resistance Level | $56.04 | $30.86 |
| Average True Range (ATR) | 2.24 | 0.25 |
| MACD | -0.37 | -0.08 |
| Stochastic Oscillator | 53.19 | 10.32 |
Price Performance
Historical ComparisonAbout PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
About CZR Caesars Entertainment Inc.
Caesars Entertainment's stand-alone portfolio includes about 50 domestic gaming properties across the Las Vegas (48% of 2025 EBITDAR) and regional (49%) markets. Additionally, the company hosts managed properties and digital assets that produced marginal EBITDA in 2025. Caesars' US presence roughly doubled with the 2020 acquisition by Eldorado, which built its first casino in Reno, Nevada, in 1973. Caesars' brands include Caesars, Harrah's, Tropicana, Bally's, Isle, and Flamingo. Also, the company owns the US portion of William Hill (it sold the international operation in 2022), a digital sports betting platform. The portfolio is set to expand to more than 60 casinos with the proposed acquisition of Caesars by Fertitta Entertainment and its Golden Nugget resorts.